Skip to content

Welcome to Discover Pharma! Today is : November 7, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Advanced Therapies

  • Advanced Therapies,Drug Discovery & Development,Therapeutic Areas

    PhoreMost unveils breakthrough platform to rationalise molecular glue drug discovery

    High-throughput GlueSEEKER platform expands druggable space by identifying novel induced [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Drug Delivery & Formulation,Opinion & Events,Therapeutic Areas

    New research partnership targets $1 malaria prevention shot using next-gen biologics

    Eyam Health, a Canadian biotech, teams with Medicines for Malaria [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Opinion & Events,Therapeutic Areas

    Neuraxpharm expands global reach with launch of Australian affiliate

    Neuraxpharm Group, a leading European specialty pharmaceutical company focused on [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development

    Sanofi to acquire Vicebio for $1.6 billion, boosting next-generation multivalent respiratory vaccines

    Sanofi has agreed to acquire Vicebio Ltd, a biotechnology company [...]

    May 5, 2026
  • Advanced Therapies,Clinical & Regulatory,Therapeutic Areas

    Novotech report explores how in-vivo CAR-T could transform cell therapy access and costs

    A new whitepaper from Novotech has outlined how in-vivo CAR-T [...]

    May 5, 2026
  • Advanced Therapies,Clinical & Regulatory,Therapeutic Areas

    AAVB-039 Gains FDA clearance to advance treatment for Stargardt Disease

    AAVantgarde’s AAVB-039 gene therapy, targeting the root cause of Stargardt [...]

    May 5, 2026
  • Advanced Therapies,Clinical & Regulatory,Therapeutic Areas

    Rare bone disorder: Novadip reports long-term success for pediatric patients treated under compassionate use programme

    Novadip Biosciences and Cliniques universitaires Saint-Luc have reported successful long-term [...]

    May 5, 2026
  • Advanced Therapies,Clinical & Regulatory

    Nanoscope Therapeutics begins FDA submission for gene-agnostic therapy to treat retinitis pigmentosa

    Nanoscope Therapeutics has initiated a rolling submission for its Biologics [...]

    May 5, 2026
  • Advanced Therapies,Clinical & Regulatory,Opinion & Events

    NICE recommends Mirikizumab for moderately to severely active Crohn’s Disease after biologic failure

    Mirikizumab is now recommended by NICE for routine NHS use [...]

    May 5, 2026
  • Advanced Therapies,Clinical & Regulatory,Drug Discovery & Development

    SPT Labtech and Semarion join forces to automate and miniaturize cell-based assays

    SPT Labtech has partnered with Semarion to integrate its firefly [...]

    May 5, 2026
Previous242526Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Brenntag signs Eastern Europe nutraceutical distribution deal
    Categories: Biotech & Pharma Business, Manufacturing & Supply Chain
  • FDA approves daraxonrasib for second-line pancreatic cancer
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics
  • PharmaForceIQ launches AI platform for pharma commercial teams
    Categories: Biotech & Pharma Business, Digital & Data
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top